Clinical Trial Update: Safety and Efficacy Study of Betamarc to Treat Loss of Weight and Appetite in Non-Small Cell Lung Cancer [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating Betamarc for loss of weight and appetite in non-small cell lung cancer; the study was terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Anorexia
• Cachexia
• Non-small Cell Lung Cancer

Drugs mentioned

• Betamarc

Snippet

Sponsor: Anaborex | Conditions: Anorexia, Cachexia | Phase 2 | Status: TERMINATED